Wojciech Jurczak, MD, PhD, head of the Department of Oncology at Maria Sklodowska-Curie National Research Institute of Oncology, discusses the changing therapy landscape for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Wojciech Jurczak, MD, PhD, head of the Department of Oncology at Maria Sklodowska-Curie National Research Institute of Oncology, discussed the changing therapy landscape for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Transcript
How might the findings of the phase 2 L-MIND study help inform clinical practice and treatment decisions for patients with relapsed or refractory DLBCL?
The perspective of relapsing/refractory diffuse large B-cell lymphoma is changing evidently. We have the dusk of classical chemotherapy as we know, including high-dose chemo, and transplant is gradually replaced by a targeted chemotherapy, molecular targeted agents, and, last but not least, immunotherapy. It is difficult to use molecular targeted agents with the present diagnostic methods—it should be noticed that even at this EHA [European Hematology Association annual meeting], there were some data on CDK9 inhibitors. The targeted chemotherapy is widely used, but what's most important is immunotherapy.
Now, the CAR [chimeric antigen receptor] T cells are approved in the third line and now are being moved to the second line of therapy. The targeted chemotherapy approved in the second line after the POLARIX study is gradually moved to the first line, with immunities like [the] TAFA-LEN [tafasitamab plus lenalidomide] regimen being reserved for the patients who are not eligible for the CAR T-cell therapies either because of age, comorbidities, or logistical problems. As this is a regimen which is excellently tolerated, we can still offer it to the majority of elderly populations, which we do not like to treat with a more harsh Pola-BR regimen, including targeted chemotherapy [polatuzumab vedotin and rituximab] together with bendamustine.
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More